Lu-wen Shi
38 Xueyuan Road
Haidian, 100191, China
Haidian, 100191, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Integrated assessment of antimicrobial stewardship in carbapenem resistant Klebsiella pneumoniae prevalent hospitals in China: a multidisciplinary surveillance network-based survey.
Journal: Antimicrobial resistance and infection control
Published: August 25, 2024
Guidelines for economic evaluation of post-marketing Chinese patent medicine
Journal: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Published: April 15, 2024
Severe Thrombocytopenia Caused by Vancomycin in the Intensive Care Unit: A Case Report.
Journal: Frontiers in medicine
Published: December 05, 2021
Risk of Liver Injury Associated with Intravenous Lipid Emulsions: A Prescription Sequence Symmetry Analysis.
Journal: Frontiers in pharmacology
Published: August 25, 2020
Drug-Related Problems Identified During Pharmacy Intervention and Consultation: Implementation of an Intensive Care Unit Pharmaceutical Care Model.
Journal: Frontiers in pharmacology
Published: June 12, 2020
Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement data.
Journal: Antimicrobial resistance and infection control
Published: November 01, 2019
Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015.
Journal: BMC health services research
Published: July 22, 2019
Optimising early nutritional support for medical inpatients.
Journal: Lancet (London, England)
Published: May 17, 2019
The impact of the clinical pharmacist-led interventions in China: A systematic review and Meta-Analysis.
Journal: International journal of clinical pharmacy
Published: April 29, 2019
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Journal: Advances in therapy
Published: January 10, 2019
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Journal: Clinical therapeutics
Published: December 03, 2018
Last Updated: 09/26/2026